bpc-157 peptide uses in regenerative medicine BPC-157: The Body Protection Compound

(2023) Phase 2 Retatrutide Trial, NEJM (PubMed) Coskun et al

Tesofensine produced weight loss significantly greater than placebo and was more effective than any currently approved obesity drug at the time. Astrup et al., The Lancet Additional Findings: The majority of weight loss came from visceral fat and abdominal adiposity Lean body mass was preserved , unlike with most appetite suppressants Participants reported reduced hunger and better diet adherence Tesofensine significantly improved waist circumference , lipid profiles, and fasting glucose These findings have led to continued interest in Tesofensines use for body recomposition not just for general weight loss, but for fat-specific reduction without muscle sacrifice

delivered quarterly

It was first described in the scientific literature in 1993 by Sikiri and colleagues

Its role in KLOW is to support the blood supply behind tissue repair rather than build collagen directly